Search

Obesity is a risk factor for a number of chronic conditions. Obesity is clinically defined using the body mass index (BMI) as weight in kg divided by (height)2 in m2 correlated with obesity. Currently, genetic markers of obesity are being studied. This study focused on the association between the angiotensin II receptor AGTR1 gene (A1166C) and fat mass and obesity-associated protein also known as alpha-ketoglutarate-dependent dioxygenase (FTO) (rs9939609) in obese children and adolescents patients in Rostov region, Russia. Five-hundreds of Russian nationality child and adolescent were recruited for the obesity-control studies. The relationship between the A1166C polymorphism of the AGTR1 gene in 300 children and adolescents included as the unhealthy group, compared with healthy group of 200 participants were investigated. Genotyping of A1166C polymorphisms of the AGTR1 rs5186 gene was performed using PCR allele-specific primers. Polymorphisms of the AGTR1 A1166C (rs5186) genes in donor DNA samples were typed by the electrophoretic method using commercial test systems from the Lytech research and production company. The relationship between obesity and AGTR1 gene polymorphism (A1166C) was not established between the obesity and control groups in terms of the frequency of occurrence of the CC genotype (P = 1.000) and (OR 1.05; 95% CI (0.53 – 2.10)) and the C allele (P = 0.942) and (OR 1.01; 95% CI (0.76 – 1.35)). However, in the occurrence of frequency genotype of AA (P = 0.003; OR 0.57; 95% CI (0.39 – 0.82)) and T (P = 0.006) of allele and (OR 1.44; 95% CI (1.11 – 1.87)) the rs9939609 of the FTO gene were revealed differences (P

Many human diseases including cancer, degenerative and autoimmune disorders, diabetes and others are multifactorial. Pharmaceutical agents acting on a single target do not provide their efficient curation. Multitargeted drugs exhibiting pleiotropic pharmacological effects have certain advantages due to the normalization of the complex pathological processes of different etiology. Extracts of medicinal plants (EMP) containing multiple phytocomponents are widely used in traditional medicines for multifactorial disorders' treatment. Experimental studies of pharmacological potential for multicomponent compositions are quite expensive and time‐consuming. In silico evaluation of EMP the pharmacological potential may provide the basis for selecting the most promising directions of testing and for identifying potential additive/synergistic effects. Multiphytoadaptogen (MPhA) containing 70 major phytocomponents of different chemical classes from 40 medicinal plant extracts has been studied in vitro, in vivo and in clinical researches. Antiproliferative and anti‐tumor activities have been shown against some tumors as well as evidence‐based therapeutic effects against age‐related pathologies. In addition, the neuroprotective, antioxidant, antimutagenic, radioprotective, and immunomodulatory effects of MPhA were confirmed. Analysis of the PASS profiles of the biological activity of MPhA phytocomponents showed that most of the predicted anti‐tumor and anti‐metastatic effects were consistent with the results of laboratory and clinical studies. Antimutagenic, immunomodulatory, radioprotective, neuroprotective and anti‐Parkinsonian effects were also predicted for most of the phytocomponents. Effects associated with positive effects on the male and female reproductive systems have been identified too. Thus, PASS and PharmaExpert can be used to evaluate the pharmacological potential of complex pharmaceutical compositions containing natural products [ABSTRACT FROM AUTHOR]

Obesity is a risk factor for a number of chronic conditions. Obesity is clinically defined using the body mass index (BMI) as weight in kg divided by (height)2 in m2 correlated with obesity. Currently, genetic markers of obesity are being studied. This study focused on the association between the angiotensin II receptor AGTR1 gene (A1166C) and fat mass and obesity-associated protein also known as alphaketoglutarate-dependent dioxygenase (FTO) (rs9939609) in obese children and adolescents patients in Rostov region, Russia. Five-hundreds of Russian nationality child and adolescent were recruited for the obesity-control studies. The relationship between the A1166C polymorphism of the AGTR1 gene in 300 children and adolescents included as the unhealthy group, compared with healthy group of 200 participants were investigated. Genotyping of A1166C polymorphisms of the AGTR1 rs5186 gene was performed using PCR allele-specific primers. Polymorphisms of the AGTR1 A1166C (rs5186) genes in donor DNA samples were typed by the electrophoretic method using commercial test systems from the Lytech research and production company. The relationship between obesity and AGTR1 gene polymorphism (A1166C) was not established between the obesity and control groups in terms of the frequency of occurrence of the CC genotype (P = 1.000) and (OR 1.05; 95% CI (0.53 – 2.10)) and the C allele (P = 0.942) and (OR 1.01; 95% CI (0.76 – 1.35)). However, in the occurrence of frequency genotype of AA (P = 0.003; OR 0.57; 95% CI (0.39 – 0.82)) and T (P = 0.006) of allele and (OR 1.44; 95% CI (1.11 – 1.87)) the rs9939609 of the FTO gene were revealed differences (P <0.05) between patients and control groups. The association between genotypes obesity risk was indicated, and a significant relationship was shown between the occurrence of obesity with the FTO rs9939609 polymorphism. [ABSTRACT FROM AUTHOR]